Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall St slips as Middle East escalations lifts oil; Trump-Xi talks in focus
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Plug Power COO resigns to join another company
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Wall Street ends down as oil prices, Treasury yields rise
Citi Downgrades Avidity Biosciences (RNA) to Neutral
October 27, 2025 10:38 AM EDTCiti analyst Geoff Meacham downgraded Avidity Biosciences (NASDAQ: RNA) from Buy to Neutral with a price target of $72.00.
For an analyst ratings summary and ratings history on Avidity Biosciences click here. For more ratings news on Avidity Biosciences click here.
Shares of Avidity Biosciences closed at $49.15 yesterday.
... More